J. Results
were analyzed through non-inferiority assessments of the average final
hemoglobin levels of the groups on extended dosing schedules compared to the
group receiving weekly dosing. Patients were required to have a stable
hemoglobin level greater than or equal to 11 grams per deciliter of blood and
to have been previously receiving Epoetin alfa for two or more months.

dietitians drownings

Golden is the President of the American Society of Apheresis
(ASFA), an organization specializing in the training and education of
apheresis practitioners.3%.

drownings ehealth

Fernandez sits on the board
of directors of ASFA. "Both Pat and Christine have demonstrated
life-long commitments to the field of apheresis and bring tremendous
expertise to our growing company.J.
The most common adverse events in any treatment group were hypertension or
high blood pressure, 6., the marketer of PROCRIT(R), supported the
study.

immunological cida

She is also the ASFA liaison to
the ASCP Board of Registry, Board of Governors.

com.

Newly Published Study Evaluates Extended Dosing Regimens of PROCRIT(R) (Epoetin alfa) as Maintenance Treatment for Patients with Anemia from Chronic Kidney Dis

, A new study published in the
August 2005 issue of Clinical Nephrology suggests that less frequent dosing of
PROCRIT(R) (Epoetin alfa) may result in a similar response to that of weekly
dosing for maintaining hemoglobin -- or red blood cell -- levels in patients
with anemia related to chronic kidney disease who are not on dialysis. Dr. Prescribing Information and additional information on
PROCRIT(R), please refer to the accompanying package insert or visit
http://www .

sharps dietitians

These
statements relate to future events and are subject to risks,
uncertainties and assumptions about the company. These statements are
only predictions based on our current expectations and projections
about future events.
This important educational event provides a forum for the exchange of new
scientific and clinical transplantation information, creates an arena for the
interchange of ideas regarding care and management of organ + tissue
transplant recipients, and facilitates discussions on numerous timely topics
in the transplantation field. Dose
reductions were made over the course of the study, but increases were not
permitted.J.

torture technologists

Golden has been
Chair of the ASFA/ASCP Hemapheresis Practitioner Certification
Examination Committee for three years. We do not undertake to
update any forward-looking statements., The sixth annual American
Transplant Congress (ATC 2005) is widely regarded as the world's premier
conference and meeting for physicians, surgeons, scientists, nurses , organ
procurement personnel and pharmacists focusing in the field of basic and
clinical transplantation .

Schedule:

Saturday, May 21 Pre-meeting Symposia

Saturday, May 21-Tuesday, May 24 Exhibits

Sunday, May 22-Wednesday, May 25 Scientific Sessions

ATC 2005 has received a record number of abstracts and the presenters
include the most respected and knowledgeable individuals in the fields of
basic and clinical transplantation science and medicine.

extracorporeal credible

PhereSys Therapeutics Expands Senior Management Team to Initiate Therapeutic Apheresis Operations Throughout the Midwest

After Fresenius Medical Care of North
America (FMC-NA) assumed control of the program, she advanced to the
position of Corporate Director of Therapeutic Apheresis . If interested, please contact Steven Schiff at
610-449-8056 or email steve@schiffmarketing.5 percent , 89. More than 20 million Americans -- or one in
nine adults -- are estimated to have this condition , and as many as two-thirds
of them develop anemia. Ortho Biotech, located in
Bridgewater, N.

psychiatrists immunological

Ms . Fernandez was the
National Director of Operations for Therapeutic Apheresis with
Fresenius Medical Care Extracorporeal Alliance, which performs over
4,500 procedures annually.
"We are extremely pleased that Pat and Christine have decided to
join our senior management team and manage our Midwest operations. Maintenance of hemoglobin
at these levels is consistent with the Kidney Disease Outcomes Quality
Initiative guidelines, published in 2001 by the National Kidney Foundation.
The incidence of adverse events was comparable across all study groups.3%; and headache, 3.

About PROCRIT (R) (Epoetin alfa)
PROCRIT(R) (Epoetin alfa) is a prescription medication for the treatment
of anemia in chronic kidney disease patients who are not on dialysis and is
injected by doctors or nurses .
In 1990, Ortho Biotech Products, L.

ihf provident

In-depth scientific material will be provided
through symposia, oral abstracts, concurrent workshops, poster presentations
and small group sessions. The primary endpoint for the
trial was the average final hemoglobin levels for patients dosed weekly , once
every two weeks, once every three weeks and once every four weeks. Drugs like PROCRIT(R) may
increase the risk of blood clots and seizures.

initiate innovating

She is active in several professional
societies , and has committee appointments to the American Society for
Clinical Pathology (ASCP) Globalization Task Force, ASFA Public
Affairs Committee, ASFA Allied Health Committee, and the American
Society for Hematology, Committee on Practice.
Fernandez is active in several professional societies and has
committee appointments to ASFA's Allied Health, International Affairs
and the Annual Meeting Planning committees.
Transplantation topics include:

-- Cardiovascular Disease
-- Artificial Heart
-- Organ Donor Management
-- Inflammation Issues
-- Allorecognition
-- Bioartificial Organs
-- T-Cell Activation
-- Immunosuppression
-- New technologies in Transplantation Immunology
-- Pediatric Transplantation
-- Renal Transplantation
-- Infectious Diseases
-- Liver Donoring
-- Reproductive issues
-- Xenotransplantation
-- Emerging viruses in organ transplants
-- Medical complications following transplantation

Visit http://www.

P.P.KidneyResource.

nephrology ehealth

"The results of the PROMPT study suggest that PROCRIT(R) may provide
sufficient hemoglobin levels in patients even when dosed less than once weekly
for maintenance therapy," said the study's principal investigator, Robert
Provenzano, MD, FACP, Division of Nephrology, St.
High blood pressure has been noted in patients treated with PROCRIT(R) and
blood pressure should be monitored carefully.

In studies, the most
common side effects were high blood pressure, headache, joint pain and nausea .

initiate nutritionists

PROCRIT(R) is not for patients with uncontrolled high blood pressure. was established in Raritan , N.

thermology provident

Currently,
Ms."
said Richard Davis, MD, Chairman and Chief Executive Officer of
PhereSys Therapeutics. At least 10 other states are
scheduled for operations in the coming year.

Forward Looking Statements

This press release may contain forward-looking statements. Saturday's Pre -
meeting Symposia includes: presentations on sensitized recipients, medical
complications, B-Cell data, infectious disease, pediatric issues, current
controversies and more. This site provides physicians , patients and caregivers
immediate access to more than 60 Web sites, many of which are operated by
non-profit, educational and patient advocacy organizations.

ehealth nutritionists

1% of patients withdrew from the study due to adverse events.
Ortho Biotech, in partnership with leading patient and professional
organizations, introduced http://www.com this year.

sharps psychiatrists

She has made numerous educational presentations
both nationally and internationally on apheresis and has authored and
co-authored a number of journal articles in the field of apheresis and
hematopoetic transplantation. Ms. BRIDGEWATER, N. The current FDA-approved
dose for adult patients with anemia related to chronic kidney disease who are
not on dialysis is 50 to 100 units per kilogram of body weight three times per
week. Loss of response to PROCRIT(R)
could be a sign of a very rare but serious condition. It is the
first -ever comprehensive directory of chronic kidney disease sites on the
World Wide Web.

sharps dietitians

Paul areas, which grew to more than
1,500 procedures per year. Currently, Ms. Their practical experiences fit
perfectly with our goal of delivering the highest quality, most
innovative therapeutic services to hospitals and physicians offices on
a national level. PhereSys is scaling up an aggressive nationwide expansion of its
business model with new initiatives now underway in Minnesota,
Illinois, Michigan, Wisconsin and Texas. You should not place undue reliance on these
statements.
Ortho Biotech Products , L.P.


About Chronic Kidney Disease
Chronic kidney disease is a progressive condition in which the kidneys are
unable to function effectively. As the kidneys' ability to function decreases , they
become unable to help the body produce red blood cells, which contain
oxygen-carrying hemoglobin , resulting in anemia.

innovating provident

The opening of the
Midwest region is a part of the Company's strategic plan to build the
nation's most comprehensive, contract mobile TA network. Ms. She is currently working on a project to
facilitate apheresis education and certification in Mexico. In addition to being the
preferred mobile provider of the RHEO(R) system, once approved by the
FDA, PhereSys' strategy involves establishing strategic relationships
with TA providers, blood banks, and TA technology companies , as well
as assisting pharmaceutical and biotech companies seeking to develop
and commercialize stem cell and other advanced cellular therapies.

American Transplant Congress 2005

"
The PROMPT study was designed to determine whether extended PROCRIT(R)
dosing schedules of up to once every four weeks are comparable to weekly
dosing in maintaining hemoglobin levels in patients with anemia related to
chronic kidney disease who are not on dialysis. Across all study groups,
16 or 3.
Since that time, Ortho Biotech and its worldwide affiliates have earned a
global reputation for researching , manufacturing and marketing innovative
products that enhance patients' health., is an established market leader in Epoetin alfa therapy for
anemia management across multiple indications and focuses its research and
marketing efforts in four clinical areas: oncology, nephrology, immunology and
surgery .

thermology thermography

Actual events or results may vary.atcmeeting. More
than 20 million Americans -- or one in nine adults -- are estimated to have
chronic kidney disease, and as many as two-thirds of these patients develop
anemia. Robert Provenzano, principal investigator of the study, is a
consultant to Ortho Biotech Products, L.

thermography dietitians

The Company currently provides its
services to hospitals and physicians' offices in California and New
York.org for more details, a complete meeting
schedule, key speakers, information , and meeting times. The study found that
approximately 90 percent of patients dosed with PROCRIT (R) once every two
weeks and more than 75 percent of patients dosed once every three or four
weeks maintained hemoglobin levels greater than or equal to 11 grams per
deciliter of blood. John Hospital and Medical
Center in Detroit, Michigan.7%;
urinary tract infection, 4. PROCRIT(R) helps treat
anemia by increasing the number of red blood cells in the body.

About Ortho Biotech Products , L.

psychiatrists innovating

-----
PhereSys Therapeutics Corporation announced today the establishment of
its Midwest Regional therapeutic apheresis (TA) operations based in
Chicago and Minneapolis.
Ms. From 2002 until recently , Ms.
Throughout the course of the study, 93.J. The site also
offers an interactive anemia awareness center, which features information
about anemia related to chronic kidney disease.

immunological summits

Ms.

Seattle Plays Host to the World's Premier Transplantation Conference

MOUNT LAUREL, N .
The dosages used in this study are not FDA approved.
The results for the groups dosed once every two weeks and once every four
weeks were statistically non-inferior to the group dosed weekly.P.

tricare parenteral

Patricia Golden, BSN, RN and Christine
Fernandez, BSN, RN have been appointed Vice Presidents and Co-Regional
Directors and bring over 40 years of combined experience in
therapeutic apheresis ('TA") to the Company. Golden was responsible for the development of the therapeutic
apheresis program at Kidney Disease and Critical Care Associates
serving the Minneapolis and St."

About PhereSys Therapeutics Corporation

PhereSys Therapeutics is a privately held company founded to
establish the premier contract mobile therapeutic apheresis services
network in the United States. Media interviews are
welcomed and can be arranged. Patients received treatment for a total of 16 weeks. Symptoms of anemia
include tiredness, dizziness and shortness of breath.S.

credible psychiatrists

Business Editors/Biotech Writers
BIOWIRE2K

EL DORADO HILLS, Calif. Fernandez was involved in the development of the Hematopoetic
Cell Transplant and Therapeutic Apheresis Programs at Riley Hospital
for Children at Indiana University Medical Center and has implemented
and monitored several apheresis and hematopoetic transplant programs
in the Chicago area.
A total of 519 patients with anemia related to chronic kidney disease not
on dialysis were enrolled in the open-label study, Clinical Evaluation of
PROCRIT (R) for Maintenance Phase Treatment of Patients with Anemia due to
Chronic Kidney Disease, referred to as the PROMPT study.8%; peripheral edema or swelling of the feet, 5. Hemoglobin is the main
measure doctors use to assess the severity of anemia.

initiate nutritionists

Golden has conducted numerous educational
programs on therapeutic apheresis and has authored and co-authored a
number of journal articles.
Patients enrolled in the PROMPT study were randomized to receive one of
four PROCRIT(R) dosing schedules: 10,000 units once weekly, 20,000 units every
two weeks, 30,000 units every three weeks or 40,000 units every four weeks.5 percent, 77.2
percent and 76 percent of patients maintained hemoglobin levels greater than
or equal to 11 grams per deciliter of blood in the weekly, once every two
weeks, once every three weeks and once every four weeks groups, respectively.PROCRIT.com.

provident drownings

This joint meeting is sponsored by the American
Society of Transplant Surgeons (ASTS) and the American Society of
Transplantation (AST) and will occur from May 21-25, 2005 at the Washington
State Convention + Trade Center in Seattle , WA.

ATC 2005 Highlights include:
-- Sunrise Symposia on Rituximab and the highly sensitized patient,
Stem Cells, the Economics of Transplantation, T-Cell discussion,
Parenchymal Cell Injury, Chronic Kidney Disease, and more
-- Immunosuppression minimization + withdrawal
-- Ethical issues in transplantation
-- Stem Cell research
-- Virology update
-- T-Cell memory and homeostasis
-- Rejection and infection issues
- - New B-Cell data
-- Organ allocation
-- Living kidney donation
-- State-of-the -Art Address - Immunology of Diabetes and Recurrence of
Autoimmunity in Post-transplantation
-- Keynote Address - Evolution of Bone Marrow Transplantation
-- In-depth reviews: Clinical - Pregnancy Registry: Specific Issues,
Poloyma Virus
Basic - NK and NK/T-Cells
-- "What's Hot, What's New" will be the feature presentation on
Wednesday, May 25

There are a variety of educational objectives with discussions centering
on, but not limited to heart, lung, kidney, pancreas and liver transplants .
The product labeling for PROCRIT(R) recommends a target hemoglobin range
of between 10 and 12 grams per deciliter of blood. "Since PROCRIT(R) is most often administered by
doctors or nurses , this finding could ultimately provide patients with anemia
related to chronic kidney disease increased convenience and flexibility when
planning their doctor visits.
For full U.

tricare ghn

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)